Symposium:
39. Stranded in Transplantation—New Inroads and Roadblocks in the Management of Double-Stranded DNA Viruses
Thursday, October 27, 2016: 10:30 AM-12:00 PM
Room: 293-296

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • outline variables that help predict and recognize antiviral resistance among herpes viruses after transplantation
  • describe management strategies for herpes and adenovirus infections after transplantation
  • discuss diagnostic methods for detecting herpes and adenovirus infections after transplantation

Target Audience: Academicians, Clinicians, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Members-in-training, Microbiologists, Nurses, Pharmacists, Researchers, Scientists, Vaccinologists

Tracks: Adult ID, Investigative ID, Epidemiology and Infection Control

Moderators:  Raymund R. Razonable, MD, FIDSA, Mayo Clinic and Francisco M. Marty, MD, FIDSA, Brigham and Women's Hospital

Presentations:
10:30 AM
105
10:55 AM
Q&A
11:00 AM
106
11:25 AM
Q&A
11:55 AM
Q&A

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-226-L01-P

Disclosures:

R. R. Razonable, None

F. M. Marty, Alexion: Scientific Advisor , Consulting fee
Ansun: Investigator , Research support
Astellas: Consultant and Investigator , Consulting fee and Research support
Basilea: Conference speaker , Speaker honorarium
Chimerix: Consultant and Investigator , Consulting fee and Research support
Gilead: Consultant and Investigator , Consulting fee and Research support
GlaxoSmithKline: Consultant and Investigator , Consulting fee and Research grant
LFB, S.A.: Consultant , Consulting fee
Merck: Consultant and Investigator , Consulting fee and Research support
Shire: Consultant and Investigator , Consulting fee and Research support
WHISCON: Investigator , Research support
Pfizer: Course speaker , Speaker honorarium
Fate Therapeutics: Scientific Advisor , Consulting fee

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.